Serum Institute to invest Rs 501 crore in Oxford Biomedica
New Delhi: Vaccine maker Serum Institute of India (SII) will invest 50 million pounds ($68 million) in Oxford Biomedica to help fund the development of a plant that manufactures COVID-19 shots, the British company said on Wednesday.
Serum - the world's largest vaccine manufacturer by volume - and Oxford Biomedica both produce AstraZeneca's COVID-19 vaccine.
Serum Life Sciences Ltd, a unit of India-based SII, will pick up a 3.9% stake in Oxford Biomedica as part of the deal.
Oxford Biomedica, spun off from Oxford University in 1995, said it would use the funds to develop the fallow area at its Oxbox plant into a manufacturing space expected to come online in mid-2023.
The Oxbox plant currently makes COVID-19 shots, and the new space is expected to include a capacity to produce viral vector-based products including vaccines, Biomedica said.
Shares of the British firm were up 5% on the London Stock Exchange, as of 0745 GMT.
Serum's investment comes four months after Oxford Biomedica doubled its sales estimates from the AstraZeneca shot to more than 100 million pounds by 2021-end.
A representative for SII did not immediately respond to Reuters' request for a comment.
For Serum, the deal is the second in as many weeks, following its planned purchase of a 15% stake in Indian drug maker Biocon's biologics unit.
The Oxford-based company said on Wednesday it swung to a profit after its half-yearly revenue more than doubled.
Medical Dialogues team had earlier reported that Novavax, Inc and Serum Institute of India Pvt. Ltd. (SII), had announced a regulatory submission to the World Health Organization (WHO) for Emergency Use Listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
Read also: Serum Institute, Novavax apply to WHO for emergency use listing of Covid-19 vaccine
Next Story